Why we should have more collaboration on HTA in Europe: the example of sofosbuvir

Saved in:

Bibliographic Details
Main Authors:	Hedi Schelleman (Author), Rudy Dupree (Author), Finn B Kristensen (Author), Wim Goettsch (Author)
Format:	Book
Published:	Taylor & Francis Group, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

MARC


LEADER	00000 am a22000003u 4500
001	doaj_caba7b54d56a44e0b4c7d5d3e8a18660
042			\|a dc
100	1	0	\|a Hedi Schelleman \|e author
700	1	0	\|a Rudy Dupree \|e author
700	1	0	\|a Finn B Kristensen \|e author
700	1	0	\|a Wim Goettsch \|e author
245	0	0	\|a Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
260			\|b Taylor & Francis Group, \|c 2015-12-01T00:00:00Z.
500			\|a 10.1186/2052-3211-8-S1-O13
500			\|a 2052-3211
546			\|a EN
690			\|a Health Technology Assessment
690			\|a Success Factor
690			\|a Eastern European Country
690			\|a Sofosbuvir
690			\|a Promising Agent
690			\|a Therapeutics. Pharmacology
690			\|a RM1-950
690			\|a Pharmacy and materia medica
690			\|a RS1-441
655	7		\|a article \|2 local
786	0		\|n Journal of Pharmaceutical Policy and Practice, Vol 8, Iss sup1 (2015)
787	0		\|n https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-O13
787	0		\|n https://doaj.org/toc/2052-3211
856	4	1	\|u https://doaj.org/article/caba7b54d56a44e0b4c7d5d3e8a18660 \|z Connect to this object online.